SIGNAL // LOADING
Loading page
Medical Director
Dr. Lena Okafor, MD
MD, MPH
Internal medicine and preventive-care physician overseeing ALUKARD's clinical standards, lab interpretation, and provider-review protocols.
Background
Clinical perspective
Dr. Lena Okafor is ALUKARD's Medical Director. Board-certified in internal medicine with a masters in public health, she leads clinical oversight for the platform's labs, hormone and metabolic pathways, and provider-review workflow. Her work focuses on translating biomarker data into concrete, defensible care plans and escalating to licensed providers only when the evidence supports it.
Specialties
- Internal medicine
- Preventive medicine
- Metabolic health
- Hormone-aware primary care
- Longevity medicine
Verification
Independently verifiable identifiers
Every reviewer on ALUKARD is traceable to public provider databases and academic profiles. Nothing on this page is a marketing stock photo.
Publications
Pages Dr. Lena Okafor, MD has authored or medically reviewed
Every item below links to the live page showing the last-reviewed date. Review scope covers clinical accuracy, source selection, and disclosure of evidence level.
Care pathway02
- Reviewer - Reviewed 2026-04-25LongevityApoB, hs-CRP, HbA1c, fasting insulin, thyroid. Re-measured every quarter. Sequenced by a provider. Never sold as a stack.
- Reviewer - Reviewed 2026-04-25CoachingProtein, sleep, training, adherence. The plumbing most routines skip, wired to your labs and your real schedule.
Learn article35
- Reviewer - Reviewed 2026-04-25GLP-1 eligibility explained: who qualifies, who doesn't, and whyThe real BMI, lab, and history criteria for semaglutide and tirzepatide - plus the reasons about 1 in 5 intakes get declined, and what to do instead.
- Reviewer - Reviewed 2026-04-25Tirzepatide vs semaglutide: how to think about the choiceSURMOUNT-1 vs STEP-1 efficacy, SURPASS vs SUSTAIN A1c deltas, GI tolerance, insurance. How to pick between tirzepatide and semaglutide.
- Reviewer - Reviewed 2026-04-25Reading a testosterone panel: what actually mattersTotal, free, and SHBG-adjusted testosterone, LH/FSH, estradiol, and the metabolic labs TRT clinics skip. How to read a panel before anyone prescribes.
- Reviewer - Reviewed 2026-04-25NAD and longevity markers: what we know, what's hypeNAD+ trial data, injectable vs oral NR/NMN, and the five labs - ApoB, HbA1c, fasting insulin, hs-CRP, Lp(a) - with the strongest longevity evidence.
- Reviewer - Reviewed 2026-04-25What a comprehensive metabolic panel actually tells youThe 14 markers on a CMP, what they flag, and the four panels - HbA1c, fasting insulin, ApoB, and thyroid - that actually complete the picture.
- Reviewer - Reviewed 2026-04-25Peptides: what they are, what they aren't, and where ALUKARD standsWhat peptides actually are, the FDA-approved vs compounded vs research-chemical divide, and the sourcing and monitoring we require before prescribing.
- Reviewer - Reviewed 2026-04-25Provider-reviewed care vs DIY supplementation: when each makes senseWhat to self-direct (foundational supplements, training, normal labs) vs where provider review is mandatory (Rx, abnormal labs, hormones).
- Reviewer - Reviewed 2026-04-25Hormone imbalance: where to start when symptoms overlapThyroid, sex hormones, ferritin, and sleep - the real drivers behind "hormone imbalance." The labs to run, how to time them, and the fixes that come before HRT.
- Reviewer - Reviewed 2026-04-25Perimenopause labs: the panel most GPs won't orderFSH, estradiol, progesterone, thyroid, ferritin, fasting insulin - the perimenopause panel cycle-timed correctly, plus what each lab actually changes about the plan.
- Reviewer - Reviewed 2026-04-25Ferritin and iron for women: the missed root cause behind fatigue and hair lossWhy "normal" ferritin at 22 ng/mL leaves you exhausted, the actual functional target (50-100), how to read the iron panel, and oral repletion that absorbs.
- Reviewer - Reviewed 2026-04-25HRT and MHT: the modern safety picture vs the 2002 headlinesTransdermal estradiol, micronized progesterone, the 10-year window, and the real numbers on breast, clot, and cardiovascular risk. What modern HRT actually looks like.
- Reviewer - Reviewed 2026-04-25PCOS labs: the markers that actually drive the planRotterdam criteria, fasting insulin, free testosterone, SHBG, DHEA-S, AMH, LH/FSH - the PCOS panel that maps insulin-driven vs adrenal vs lean phenotypes.
Plus 23 more learn articles.
Compare guide13
- Reviewer - Reviewed 2026-04-25Tirzepatide vs semaglutide: how to decideSURMOUNT-1 vs STEP-1 results, A1c reductions, tolerance, and access. How to pick between tirzepatide and semaglutide - and when labs come first.
- Reviewer - Reviewed 2026-04-25Basic vs comprehensive lab panels: what you actually needCMP and CBC vs a full preventive panel with ApoB, HbA1c, fasting insulin, and hormones. What each catches, misses, and when to run each.
- Reviewer - Reviewed 2026-04-25Provider-reviewed care vs DIY supplementation: when each makes senseWhen DIY supplementation is the right call, when provider review is mandatory, and how to decide before you order Rx from the internet.
- Reviewer - Reviewed 2026-04-25Peptides vs SARMs: what ALUKARD will and won't supportProvider-reviewed peptides vs SARMs sold "for research only." Legal status, monitoring, known harm profiles, and the line ALUKARD won't cross.
- Reviewer - Reviewed 2026-04-25Injectable NAD+ vs oral precursors: picking a format that actually raises NADSubQ NAD+ vs oral NR and NMN: human evidence, dosing, monitoring, and cost. Plus why ALUKARD skips IV NAD+ today.
- Reviewer - Reviewed 2026-04-25Ozempic vs Wegovy: same molecule, different labelsSame semaglutide molecule, different labels and coverage paths. Ozempic for type 2 diabetes, Wegovy for weight. How to pick the right lane.
- Reviewer - Reviewed 2026-04-25Compounded vs branded GLP-1: sourcing, cost, and what to trustBranded GLP-1s are FDA-approved. Compounded versions use the same peptide without FDA efficacy review. Cost, legality, and sourcing compared.
- Reviewer - Reviewed 2026-04-25Sildenafil vs tadalafil: which PDE5 inhibitor fits your lifeShort-window on-demand vs 24-36 hour flexibility or daily dosing. Response rates, side effects, food sensitivity, and when labs come first.
- Reviewer - Reviewed 2026-04-25TRT at a clinic vs supervised telehealth: what the eligibility bar actually isEligibility bar, monitoring cadence, estradiol management, fertility, and cost. How in-person TRT and supervised telehealth actually compare.
- Reviewer - Reviewed 2026-04-25HRT routes: transdermal vs oral vs pelletTransdermal, oral, and pellet HRT compared: first-pass metabolism, VTE, dose control, and who each route fits. Modern MHT guidance, demystified.
- Reviewer - Reviewed 2026-04-25ALUKARD vs Hims: protocol depth versus speed and simplicityComparing ALUKARD and Hims on intake depth, lab-first planning, protocol transparency, and the trade-off between speed and precision.
- Reviewer - Reviewed 2026-04-25ALUKARD vs Ro: eligibility rigor versus rapid telehealth flowHow ALUKARD and Ro compare on eligibility rigor, lab integration, monitoring structure, and when each telehealth model is the better fit.
Plus 1 more compare guide.
Protocol07
- Reviewer - Reviewed 2026-04-29Insulin resistance reversal stackHow ALUKARD structures pre-diabetes and metabolic-syndrome reversal: HOMA-IR-driven phenotype, structured lifestyle compression, and a 16-24 week decision point before GLP-1.
- Author - Reviewed 2026-04-29Subclinical thyroid optimization stackHow ALUKARD structures subclinical thyroid workup: full panel including reverse T3 and TPO, upstream confounder correction, and ATA-criteria-aligned decision to treat.
- Author - Reviewed 2026-04-29Sleep and cortisol recovery stackHow ALUKARD structures sleep and cortisol recovery: 14-day baseline, CBT-I-aligned stimulus control, full HPA panel, and a re-measure-and-personalize phase before any sedatives.
- Author - Reviewed 2026-04-29VO2max progression and Zone-2 stackHow ALUKARD structures VO2max progression: baseline measurement, polarized Zone-2 base, polarized interval blocks, and a 12-16 week retest target.
- Reviewer - Reviewed 2026-04-29Sarcopenia and lean-mass preservation stackHow ALUKARD structures sarcopenia prevention: DEXA + grip baseline, protein floor, progressive resistance training, creatine support, and re-measurement at 16-24 weeks.
- Reviewer - Reviewed 2026-04-27Longevity foundational biomarker stackA quarterly longevity loop centered on ApoB, insulin, inflammation, and thyroid markers before advanced protocol stacking. Data first, hype last.
- Author - Reviewed 2026-04-27Post-GLP-1 maintenance stackA structured transition after GLP-1: taper planning, appetite-rebound control, coaching cadence, and lab-guided maintenance to reduce regain risk.